1AD.AX

Healthcare Biotechnology

AdAlta Limited

A$0.00

-0.00 -12.50% today

Price History

Not enough data

Key Stats

Market Cap

11.24M

Avg Volume

1.50M

52W High

A$0.01

52W Low

A$0.00

Div. Yield

0.0%

Valuation

Forward P/E

-0.12

P/S Ratio

27.81

EV/EBITDA

-2.68

EV/Revenue

28.61

Margins

Gross Margin 32.1%

Operating Margin (2251.0%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(67.5%)

Return on Assets

(142.3%)

Liquidity & Leverage

Current Ratio

1.27

Quick Ratio

1.15

Total Cash

1.28M

Total Debt

About

AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.